Hennessy Advisors Inc. Has $16.01 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Hennessy Advisors Inc. lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 726,600 shares of the company’s stock after purchasing an additional 46,300 shares during the period. Hennessy Advisors Inc. owned 0.06% of Teva Pharmaceutical Industries worth $16,014,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after buying an additional 20,762,226 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after acquiring an additional 2,204,623 shares during the period. State Street Corp lifted its position in Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 3.4% during the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock valued at $157,571,000 after acquiring an additional 291,124 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of Teva Pharmaceutical Industries by 7,945.2% in the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after purchasing an additional 4,732,374 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TEVA shares. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Finally, Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.13.

Teva Pharmaceutical Industries Trading Down 1.2 %

Shares of TEVA opened at $21.68 on Friday. The stock has a 50 day simple moving average of $19.14 and a 200-day simple moving average of $18.16. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The stock has a market cap of $24.56 billion, a PE ratio of -25.50, a PEG ratio of 1.06 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a 1 year low of $10.83 and a 1 year high of $22.80.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.